Reuters, December 1, 2016. Researchers evaluated studies done on 18 cancer drugs approved between 2008 and 2012 by the FDA. None of the drugs had been found to prolong life, and only one had enough evidence to say it improved quality of life. Yet, all but one retained its approval status.
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
To Fund Projects Like the Cancer Moonshot, Congress Had to Strip Away Some of the FDA’s Most Important Regulatory Powers
Quartz, December 1, 2016. The 21st Century Cures Act passed in the House, but comes with a lot of regulatory compromise and threats to patient safety. Most notably, Senator Warren and Senator Sanders oppose the bill along with NCHR President Diana Zuckerman due to patient safety concerns and breaks for Big Pharma. “It really is a David and Goliath issue of where the money is,” said Dr. Zuckerman.
Read More »Congress Poised To Pass Sweeping Law Covering FDA And NIH
NPR and WBUR, November 29, 2016. NCHR President, Diana Zuckerman, says she’s concerned that the 21st Century Cures act will make it even easier for drug companies to use the express lane for approval.
Read More »Lawmakers Try for Year-End Bill on Medical Research, Devices and Opioid Addiction
Wall Street Journal, November 30, 2016. Negotiators still need to hammer out agreement in some areas, including GOP proposals for limiting FDA regulation.
Read More »A Frenzy of Lobbying on 21st Century Cures
Kaiser Health News, November 28, 2016. Beyond the pharmaceutical industry, the bill’s supporters include universities, medical schools and groups representing them, as well as patient groups funded by drug and device companies. “It really is a David and Goliath issue of where the money is,” NCHR president Diana Zuckerman said.
Read More »